Henry Schein, Inc. (HSIC) News

Henry Schein, Inc. (HSIC): $74.61

0.48 (+0.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter HSIC News Items

HSIC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HSIC News Highlights

  • HSIC's 30 day story count now stands at 37.
  • Over the past 29 days, the trend for HSIC's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
  • AMN, BAX and BDX are the most mentioned tickers in articles about HSIC.

Latest HSIC News From Around the Web

Below are the latest news stories about Henry Schein Inc that investors may wish to consider to help them evaluate HSIC as an investment opportunity.

Should Value Investors Buy These Medical Stocks?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Yahoo | January 19, 2022

Leith Wheeler Investment Counsel Ltd. Buys Booz Allen Hamilton Holding Corp, Henry Schein Inc, ...

Vancouver, A1, based Investment company Leith Wheeler Investment Counsel Ltd. (Current Portfolio) buys Booz Allen Hamilton Holding Corp, Henry Schein Inc, Frontdoor Inc, Global Payments Inc, Accenture PLC, sells Jefferies Financial Group Inc, Hilton Grand Vacations Inc, iShares MSCI EAFE ETF, Charles Schwab Corp, Shopify Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Leith Wheeler Investment Counsel Ltd..

Yahoo | January 18, 2022

Returns On Capital At Henry Schein (NASDAQ:HSIC) Paint A Concerning Picture

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...

Yahoo | January 18, 2022

Intuitive Surgical (ISRG) Posts Robust Preliminary Q4 Results

Intuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2021 results driven primarily by da Vinci procedure volume growth.

Yahoo | January 17, 2022

AMN Healthcare (AMN) Reports Solid Preliminary Q4 Revenues

AMN Healthcare's (AMN) solid fourth-quarter results are likely to have been boosted by solid segmental performances.

Yahoo | January 14, 2022

DexCom (DXCM) Posts Solid Preliminary Q4 and 2021 Revenues

DexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

Yahoo | January 11, 2022

BD (BDX) Product Gets FDA Nod, Patient Outcome to Get a Boost

Regulatory clearance for BD's (BDX) Kiestra IdentifA system is expected to lead to better patient management via automated sample processing and MALDI target preparation.

Yahoo | January 10, 2022

Henry Schein rises on upgrade by Credit Suisse

No summary available.

Seeking Alpha | January 7, 2022

Here's Why You Should Retain Baxter (BAX) Stock For Now

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Yahoo | January 7, 2022

HSIC vs. COO: Which Stock Should Value Investors Buy Now?

HSIC vs. COO: Which Stock Is the Better Value Option?

Yahoo | January 6, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.9552 seconds.